Science & Technology in Action

Sanofi Aventis

Sanofi-aventis is Europe’s No.1 pharmaceutical company and No.3 in the world and is a major player across seven therapeutic areas: Cardiovascular (e.g. arterial hypertension, atrial fibrillation, peripheral arterial disease, heart failure, venous and arterial thrombosis, angina)
  • Thrombosis (e.g. venous and arterial thrombosis)
  • Metabolic disorders (e.g. Type 1 and Type 2 diabetes, Cardiometabolic Risk Factors)
  • Oncology (e.g. colorectal, breast cancer, non-small cell lung, prostate, Head and Neck and gastric Cancers)
  • Central nervous system (e.g. insomnia, multiple sclerosis, epilepsy)
  • Internal medicine (e.g. bacterial, viral and parasitic infections, osteoporosis, allergy and benign prostate disease)
  • Vaccine (e.g. travel, influenza, meningitis and poliomyelitis vaccines)

Of nearly 100,000 staff within sanofi-aventis worldwide, in 100 countries and 300 sites, over 17,600 work in research & development (R&D), developing new effective and well-tolerated medicines. In fact, sanofi-aventis has one of the most innovative and healthiest R&D portfolios with 127 compounds and vaccines under development—56 of which are already in very advanced phases. 
The sanofi-aventis commitment to bringing better healthcare solutions to populations around the globe is also guaranteed through extensive programmes in humanitarian aid and solidarity agencies. As well as tiered pricing for different socio-economic environments a number of action plans are in place, particularly in the southern hemisphere, to combat illnesses such as sleeping sickness, leishmaniasis, tuberculosis, epilepsy and malaria.